Deborah Mulford
Concepts (74)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Antibodies, Monoclonal | 4 | 2004 | 241 |
Why?
|
Leukemia, Myeloid, Acute | 5 | 2008 | 53 |
Why?
|
Radioimmunotherapy | 3 | 2004 | 6 |
Why?
|
Radioisotopes | 2 | 2005 | 28 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2004 | 121 |
Why?
|
Aminoglycosides | 1 | 2008 | 12 |
Why?
|
Leukemia, Myeloid | 2 | 2004 | 37 |
Why?
|
Alpha Particles | 2 | 2005 | 4 |
Why?
|
Drug Delivery Systems | 1 | 2005 | 55 |
Why?
|
Antineoplastic Agents | 3 | 2008 | 190 |
Why?
|
Neoplasms | 1 | 2005 | 239 |
Why?
|
Cytarabine | 3 | 2008 | 32 |
Why?
|
Clinical Trials as Topic | 2 | 2005 | 251 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2008 | 31 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2011 | 8 |
Why?
|
Thalidomide | 1 | 2011 | 12 |
Why?
|
Protease Inhibitors | 1 | 2011 | 39 |
Why?
|
Boronic Acids | 1 | 2011 | 16 |
Why?
|
Pyrazines | 1 | 2011 | 20 |
Why?
|
Chromosome Deletion | 1 | 2011 | 46 |
Why?
|
Bismuth | 1 | 2010 | 1 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2011 | 61 |
Why?
|
Treatment Outcome | 3 | 2005 | 661 |
Why?
|
Myelodysplastic Syndromes | 1 | 2011 | 27 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2008 | 17 |
Why?
|
Antigens, CD45 | 1 | 2008 | 30 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2008 | 16 |
Why?
|
Cell Adhesion Molecules | 1 | 2008 | 48 |
Why?
|
DNA Mutational Analysis | 1 | 2008 | 110 |
Why?
|
Pyrimidines | 1 | 2008 | 49 |
Why?
|
Piperazines | 1 | 2008 | 57 |
Why?
|
Acute Disease | 2 | 2004 | 271 |
Why?
|
Antigens, CD | 1 | 2008 | 128 |
Why?
|
Radiopharmaceuticals | 1 | 2005 | 37 |
Why?
|
Aged | 4 | 2008 | 988 |
Why?
|
Humans | 8 | 2004 | 1856 |
Why?
|
Nuclear Proteins | 1 | 2008 | 139 |
Why?
|
Mutation | 1 | 2008 | 340 |
Why?
|
Practice Guidelines as Topic | 1 | 2005 | 174 |
Why?
|
Physician's Practice Patterns | 1 | 2005 | 149 |
Why?
|
Drug Administration Schedule | 2 | 2008 | 191 |
Why?
|
Animals | 2 | 2004 | 1031 |
Why?
|
Aged, 80 and over | 2 | 2010 | 599 |
Why?
|
Benzenesulfonates | 1 | 2011 | 8 |
Why?
|
Farnesyltranstransferase | 1 | 2011 | 9 |
Why?
|
Arsenicals | 1 | 2011 | 7 |
Why?
|
Middle Aged | 3 | 2008 | 1161 |
Why?
|
Azacitidine | 1 | 2011 | 13 |
Why?
|
Oxides | 1 | 2011 | 21 |
Why?
|
Pyridines | 1 | 2011 | 61 |
Why?
|
Immunoconjugates | 1 | 2010 | 11 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2010 | 29 |
Why?
|
Remission Induction | 1 | 2010 | 64 |
Why?
|
Hematopoietic Stem Cells | 1 | 2011 | 69 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 208 |
Why?
|
Cladribine | 1 | 2008 | 7 |
Why?
|
Survival Rate | 1 | 2011 | 250 |
Why?
|
Blast Crisis | 1 | 2008 | 12 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2008 | 34 |
Why?
|
Disease-Free Survival | 1 | 2008 | 102 |
Why?
|
Exons | 1 | 2008 | 91 |
Why?
|
Cell Proliferation | 1 | 2011 | 227 |
Why?
|
Male | 3 | 2008 | 1553 |
Why?
|
Cytokines | 1 | 2011 | 207 |
Why?
|
Female | 3 | 2008 | 1643 |
Why?
|
Bone Marrow | 1 | 2008 | 109 |
Why?
|
Recurrence | 1 | 2008 | 261 |
Why?
|
Polymerase Chain Reaction | 1 | 2008 | 279 |
Why?
|
Apoptosis | 1 | 2011 | 265 |
Why?
|
Reproducibility of Results | 1 | 2008 | 391 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 427 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 431 |
Why?
|
Adult | 2 | 2008 | 1317 |
Why?
|
Time Factors | 1 | 2008 | 896 |
Why?
|
